Porto, Portugal — FASTinov, a company developing rapid antimicrobial susceptibility testing, completed its pre-Series A financing, raising €3.5 million from private investors.
The round included Explorer Investments, which had initially invested in FASTinov in 2022, and Quilaban, a diagnostics company with an established track record in clinical microbiology distribution. Quilaban had previously partnered with FASTinov in Portugal and further demonstrated confidence in the company’s vision by becoming an investor.
Explorer Investments described the round as support for FASTinov’s R&D pipeline and commercialization. Quilaban framed its investment as part of its wider commitment to innovation in clinical diagnostics.Statements attributed to representatives of Explorer Investments and Quilaban in the original announcement
The financing reflected growing recognition of FASTinov’s healthcare solutions and was intended to accelerate the delivery of actionable antimicrobial susceptibility results to European healthcare providers while preparing other markets.
FASTinov CEO Nuno Afonso welcomed the backing and said it would give the company additional resources to advance its work in sepsis management.
The funding programme focused on research and development, commercialization and continued development of rapid antimicrobial susceptibility testing solutions.
